Intranasal oxytocin compensates for estrus cycle-specific reduction of conditioned safety memory in rats: Implications for psychiatric disorders.
Anxiety disorder
Corticosterone
Fear
Fear inhibition
Oxytocin
Safety learning
Journal
Neurobiology of stress
ISSN: 2352-2895
Titre abrégé: Neurobiol Stress
Pays: United States
ID NLM: 101643409
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
11
11
2020
revised:
06
02
2021
accepted:
25
02
2021
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
30
3
2021
Statut:
epublish
Résumé
Stress and anxiety disorder patients frequently fail to benefit from psychotherapies which often consist of inhibitory fear learning paradigms. One option to improve the therapy outcome is medication-enhanced psychotherapy. Research in humans and laboratory rodents has demonstrated that oxytocin (OT) reduces fear and facilitates fear extinction. However, the role of OT in conditioned safety learning, an understudied but highly suitable type of inhibitory fear learning, remains to be investigated. The present study aimed at investigating the effect of intranasal OT on conditioned safety. To test this, Sprague Dawley rats (♂n = 57; ♀n = 72) were safety conditioned. The effects of pre-training or pre-testing intranasal OT on conditioned safety and contextual fear, both measured by the acoustic startle response, and on corticosterone plasma levels were assessed. Furthermore, the involvement of the estrous cycle was analyzed. The present data show that intranasal OT administration before the acquisition or recall sessions enhanced conditioned safety memory in female rats while OT had no effects in male rats. Further analysis of the estrus cycle revealed that vehicle-treated female rats in the metestrus showed reduced safety memory which was compensated by OT-treatment. Moreover, all vehicle-treated rats, regardless of sex, expressed robust contextual fear following conditioning. Intranasal OT-treated rats showed a decrease in contextual fear, along with reduced plasma corticosterone levels. The present data demonstrate that intranasal OT has the capacity to compensate deficits in safety learning, along with a reduction in contextual fear and corticosterone levels. Therefore, add-on treatment with intranasal OT could optimize the therapy of anxiety disorders.
Identifiants
pubmed: 33778132
doi: 10.1016/j.ynstr.2021.100313
pii: S2352-2895(21)00021-7
pmc: PMC7985696
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100313Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Both authors have no biomedical financial interests or potential conflicts of interest.
Références
Neuron. 2010 Mar 25;65(6):768-79
pubmed: 20346754
Psychoneuroendocrinology. 2004 Aug;29(7):883-90
pubmed: 15177703
Behav Neurosci. 2000 Feb;114(1):64-76
pubmed: 10718262
Proc Natl Acad Sci U S A. 2010 May 18;107(20):9418-23
pubmed: 20439732
Nat Rev Neurosci. 2015 Jun;16(6):317-31
pubmed: 25991441
Transl Psychiatry. 2020 Apr 24;10(1):120
pubmed: 32332716
Neuropsychopharmacology. 2014 Feb;39(3):515-27
pubmed: 23963118
Depress Anxiety. 2010 Mar;27(3):244-51
pubmed: 20143428
Biol Psychiatry. 2003 Dec 15;54(12):1389-98
pubmed: 14675803
Endocrinology. 2012 Jul;153(7):3337-44
pubmed: 22562172
Neuropsychopharmacology. 2011 Nov;36(12):2488-97
pubmed: 21796104
Psychoneuroendocrinology. 2013 Oct;38(10):1985-93
pubmed: 23579082
Nat Rev Neurosci. 2011 Aug 19;12(9):524-38
pubmed: 21852800
Cell. 2016 Sep 22;167(1):60-72.e11
pubmed: 27641503
Science. 2005 Apr 8;308(5719):245-8
pubmed: 15821089
Pharmacol Ther. 2019 Dec;204:107402
pubmed: 31470029
Biol Psychiatry. 2013 Feb 15;73(4):371-8
pubmed: 23158459
J Neurosci. 2004 Mar 24;24(12):2974-82
pubmed: 15044536
Psychopharmacology (Berl). 2012 Sep;223(2):149-58
pubmed: 22526533
J Comp Neurol. 2002 Oct 21;452(3):276-87
pubmed: 12353223
Dialogues Clin Neurosci. 2015 Jun;17(2):191-206
pubmed: 26246793
Neuropharmacology. 2020 Aug 15;173:108130
pubmed: 32389750
Biol Psychiatry. 2015 Aug 1;78(3):194-202
pubmed: 25542304
Neuropsychopharmacology. 2016 May;41(6):1495-504
pubmed: 26404844
Int J Neuropsychopharmacol. 2013 Mar;16(2):255-60
pubmed: 22647521
Biol Mood Anxiety Disord. 2012 Feb 07;2:3
pubmed: 22738383
J Vis Exp. 2012 Sep 15;(67):e4389
pubmed: 23007862
Nat Rev Dis Primers. 2017 May 04;3:17024
pubmed: 28470168
Eur Neuropsychopharmacol. 2019 Dec;29(2):266-277
pubmed: 30554861
Front Endocrinol (Lausanne). 2015 Oct 15;6:160
pubmed: 26528239
Psychopharmacology (Berl). 2020 Jul;237(7):2161-2172
pubmed: 32363439
Neuropsychopharmacology. 2010 Dec;35(13):2607-16
pubmed: 20844476
Ann N Y Acad Sci. 2003 Dec;1007:54-63
pubmed: 14993040
Cell Tissue Res. 2013 Oct;354(1):287-95
pubmed: 23525740
Science. 2011 Jul 1;333(6038):104-7
pubmed: 21719680
Nat Neurosci. 2002 Jun;5(6):514-6
pubmed: 11992114
Horm Behav. 2006 Nov;50(4):539-49
pubmed: 16904674
Neuron. 2005 Apr 21;46(2):309-20
pubmed: 15848808
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3216-3221
pubmed: 28265059
Neuropsychopharmacology. 2012 May;37(6):1534-47
pubmed: 22334122
Physiol Behav. 2014 Apr 22;129:287-96
pubmed: 24631553
Hippocampus. 2009 Nov;19(11):1142-50
pubmed: 19338017
Learn Mem. 2015 Apr 15;22(5):247-57
pubmed: 25878137
Behav Brain Res. 2020 Sep 1;393:112799
pubmed: 32649977
Neuropsychopharmacology. 2016 Jul;41(8):2041-51
pubmed: 26741286
Psychoneuroendocrinology. 2011 Sep;36(8):1114-26
pubmed: 21429671
Biol Psychiatry. 2011 Nov 15;70(10):920-7
pubmed: 21762880
Psychoneuroendocrinology. 2015 Jan;51:112-21
pubmed: 25305547
J Neurosci. 2007 Sep 5;27(36):9729-35
pubmed: 17804633
Int J Psychophysiol. 2019 Feb;136:5-14
pubmed: 29964070
Biol Psychiatry. 2002 Nov 15;52(10):958-75
pubmed: 12437937
Curr Opin Behav Sci. 2018 Oct;23:136-142
pubmed: 31745496
Genes Brain Behav. 2020 Mar;19(3):e12621
pubmed: 31661603
Behav Brain Res. 2021 Mar 26;402:113105
pubmed: 33417995
Neuropharmacology. 2012 Jan;62(1):398-405
pubmed: 21871467
Prog Neurobiol. 2009 Jun;88(2):127-51
pubmed: 19482229
Front Neuroendocrinol. 2016 Jan;40:1-23
pubmed: 25951955
Brain Res Mol Brain Res. 2002 Dec 30;109(1-2):84-94
pubmed: 12531518
Philos Trans R Soc Lond B Biol Sci. 2006 Dec 29;361(1476):2215-28
pubmed: 17118934
Behav Res Ther. 2009 Feb;47(2):111-8
pubmed: 19027893